

Special Issue

Biomarkers for Oncogenic Viruses

Message from the Guest Editors

Biomarkers have become key tools for detecting cancers caused by viruses and lesions. Besides the detection of viruses and their products, host proteins that are altered in their expression are beneficial for discriminating virally caused cancers from other cancers. Emerging technologies are expanding our abilities to detect precancerous lesions and cancers associated with human tumor viruses and to monitor their recurrence and tumor microenvironment, including liquid biopsies, single cell and/or spatial transcriptomics/proteomics, highly sensitive in situ hybridization techniques, and high-dimensional multiplex flow cytometry, among others. These emerging tools are useful at detecting not only biomarkers for virus-associated cancers at an early stage and at diagnosis, but also biomarkers for recurrence and patient response to therapies. We welcome primary papers and reviews that help move the field of biomarkers of oncogenic viruses forward.

Guest Editors

Prof. Dr. Paul F. Lambert

Director of McArdle Laboratory for Cancer Research/Chair of Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA

Dr. Wei Wang

McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA

Deadline for manuscript submissions

closed (30 November 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/172759

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).